Search Results - "Boggild, M"

EFNS guidelines on diagnosis and management of neuromyelitis optica by Sellner, J., Boggild, M., Clanet, M., Hintzen, R. Q., Illes, Z., Montalban, X., Du Pasquier, R. A., Polman, C. H., Sorensen, P. S., Hemmer, B.

“…Background and purpose:  Neuromyelitis optica (NMO) or Devic′s disease is a rare inflammatory and demyelinating autoimmune disorder of the central nervous…”
Get full text

Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it? by Ellis, R, Boggild, M

“…Background Therapy-related acute leukaemia (TRAL) is a concern for neurologists and patients when considering treatment with Mitoxantrone for multiple…”
Get full text

Treatment of MOG antibody associated disorders: results of an international survey by Whittam, D. H., Karthikeayan, V., Gibbons, E., Kneen, R., Chandratre, S., Ciccarelli, O., Hacohen, Y., de Seze, J., Deiva, K., Hintzen, R. Q., Wildemann, B., Jarius, S., Kleiter, I., Rostasy, K., Huppke, P., Hemmer, B., Paul, F., Aktas, O., Pröbstel, A. K., Arrambide, G., Tintore, M., Amato, M. P., Nosadini, M., Mancardi, M. M., Capobianco, M., Illes, Z., Siva, A., Altintas, A., Akman-Demir, G., Pandit, L., Apiwattankul, M., Hor, J. Y., Viswanathan, S., Qiu, W., Kim, H. J., Nakashima, I., Fujihara, K., Ramanathan, S., Dale, R. C., Boggild, M., Broadley, S., Lana-Peixoto, M. A., Sato, D. K., Tenembaum, S., Cabre, P., Wingerchuk, D. M., Weinshenker, B. G., Greenberg, B., Matiello, M., Klawiter, E. C., Bennett, J. L., Wallach, A. I., Kister, I., Banwell, B. L., Traboulsee, A., Pohl, D., Palace, J., Leite, M. I., Levy, M., Marignier, R., Solomon, T., Lim, M., Huda, S., Jacob, A.

“…Introduction While monophasic and relapsing forms of myelin oligodendrocyte glycoprotein antibody associated disorders (MOGAD) are increasingly diagnosed…”
Get full text

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort by Cossburn, M, Pace, A A, Jones, J, Ali, R, Ingram, G, Baker, K, Hirst, C, Zajicek, J, Scolding, N, Boggild, M, Pickersgill, T, Ben-Shlomo, Y, Coles, A, Robertson, N P

“…To define the rate, timing, and clinical risk factors for the development of autoimmune disease (AID) after alemtuzumab treatment for multiple sclerosis (MS)…”
Get full text

Anti-spasticity agents for multiple sclerosis by Shakespeare, D T, Young, C A, Boggild, M

“…Spasticity is a common problem in MS patients causing pain, spasms, loss of function and difficulties in nursing care. A variety of oral and parenteral…”
Get more information

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort by COSSBURN, M, PACE, A. A, PICKERSGILL, T, BEN-SHLOMO, Y, COLES, A, ROBERTSON, N. P, JONES, J, ALI, R, INGRAM, G, BAKER, K, HIRST, C, ZAJICEK, J, SCOLDING, N, BOGGILD, M

Get full text

Differential integrin expression regulates cell sensing of the matrix nanoscale geometry by Di Cio, Stefania, Bøggild, Thea M.L., Connelly, John, Sutherland, Duncan S., Gautrot, Julien E.

“…[Display omitted] The nanoscale geometry and topography of the extra-cellular matrix (ECM) is an important parameter controlling cell adhesion and phenotype…”
Get full text

Nurse led telephone assessment of expanded disability status scale assessment in MS patients at high levels of disability by Huda, S, Cavey, A, Izat, A, Mattison, P, Boggild, M, Palace, J

“…Abstract Background In clinical trials drop out bias reduces the validity of results. This is a particular problem in long-term multiple sclerosis (MS)…”
Get full text

The epidemiology of multiple sclerosis in the Isle of Man: 2006-2011 by Simpson Jr, S., Mina, S., Morris, H., Mahendran, S., Taylor, B., Boggild, M.

“…Background We sought to determine the prevalence of MS on the Isle of Man in 2006 and 2011, and the incidence and mortality rates over this interval. Methods…”
Get full text

Susceptibility and outcome in MS: Associations with polymorphisms in pigmentation-related genes by PARTRIDGE, J. M, WEATHERBY, S. J. M, WOOLMORE, J. A, HIGHLAND, D. J, FRYER, A. A, MANN, C. L. A, BOGGILD, M. D, OLLIER, W. E. R, STRANGE, R. C, HAWKINS, C. P

“…Multiple sclerosis (MS) risk is determined by environment and genes. The authors investigated in 419 cases and 422 controls if polymorphism in the vitamin D…”
Get full text

A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment by Craig, J, Young, C A, Ennis, M, Baker, G, Boggild, M

“…Background: There is evidence to support both the use of intravenous methylprednisolone (IVMP) in multiple sclerosis (MS) relapse and physiotherapy in the…”
Get full text

PAW25 A single-centre, pilot, randomised controlled trial of recombinant human erythropoietin in primary progressive multiple sclerosis by Karpha, I, Ramtahal, J, Boggild, M, Evans, F

“…IntroductionThere is currently no disease modifying therapy for PPMS, which constitutes 10–15% of MS cases. rhEPO is has previously been suggested to have a…”
Get full text

A randomized controlled trial of a health promotion education programme for people with multiple sclerosis by Ennis, M, Thain, J, Boggild, M, Baker, G A, Young, C A

“…Objective: To evaluate the effectiveness of a health promotion education programme for people with multiple sclerosis (the OPTIMISE programme) in terms of…”
Get full text

Vitamin D receptor gene polymorphism is associated with reduced disability in multiple sclerosis by Mamutse, G, Woolmore, J, Pye, E, Partridge, J, Boggild, M, Young, C, Fryer, A, Hoban, PR, Rukin, N, Alldersea, J, Strange, RC, Hawkins, CP

“…Ultraviolet radiation (UVR) may contribute to multiple sclerosis (MS) outcome by a mechanism involving vitamin D and the vitamin D receptor (VDR). In 512…”
Get full text

Glutathione S-transferase polymorphisms in MS: Their relationship to disability by MANN, C. L. A, DAVIES, M. B, BOGGILD, M. D, ALLDERSEA, J, FRYER, A. A, JONES, P. W, KO, C. K, YOUNG, C, STRANGE, R. C, HAWKINS, C. P

“…Oxidative stress has been implicated in inflammatory demyelination. The glutathione S-transferase (GST) supergene family encodes isoenzymes that appear to be…”
Get full text

A window of opportunity for no treatment in early multiple sclerosis? by Gilmore, CP, Cottrell, DA, Scolding, NJ, Wingerchuk, DM, Weinshenker, BG, Boggild, M.

Get full text

The role of the PTPRC (CD45) mutation in the development of multiple sclerosis in the North West region of the United Kingdom by Nicholas, R S, Partridge, J, Donn, R P, Hawkins, C, Boggild, M D

“…Background: A point mutation in protein tyrosine phosphatase receptor, type c polypeptide (PTPRC) has been associated with familial multiple sclerosis. This CG…”
Get full text

PATU7 Autoimmune diseases after alemtuzumab treatment for multiple sclerosis: findings from a multicentre UK cohort by Cossburn, M D, Pace, A A, Jones, J, Ali, R, Ingram, G, Baker, K, Hirst, C, Zajicek, J, Scolding, N, Boggild, M, Pickersgill, T, Coles, A, Ben-Shlomo, Y, Robertson, N P

“…Alemtuzumab is a anti-CD52 humanised monoclonal antibody shown to be an effective treatment for relapsing multiple sclerosis (MS) in phase II studies but…”
Get full text

Molecular genetic studies of sporadic pituitary tumors by Boggild, M D, Jenkinson, S, Pistorello, M, Boscaro, M, Scanarini, M, McTernan, P, Perrett, C W, Thakker, R V, Clayton, R N

“…Tumor formation may result from the activation of dominant oncogenes or by inactivation of recessive, tumor suppressor genes. The role of such mutations in the…”
Get more information

Studies of associations between disability in multiple sclerosis, skin type, gender and ultraviolet radiation by Woolmore, J.A., Stone, M., Pye, E.M., Partridge, J.M., Boggild, M., Young, C., Jones, P.W., Fryer, A.A., Hawkins, C.P., Strange, R.C.

“…Recent studies suggest ultraviolet radiation (UVR)/vitamin D is protective against the development of multiple sclerosis (MS). We determined if outcome in MS…”
Get full text